Navigation Links
Drug Advertising needs to be Limited

The American Medical Association has called for moratoriums on consumer advertising which promotes new drugs and medical devices until it is shown that the products// are safe and that they work.

The American Medical Association, U.S. largest physicians' group has urged the U.S. Food and Drug Administration to instruct manufacturers to complete an unspecified waiting period after a drug or device obtains regulatory approval before direct-to-consumer advertising is launched on television, in print, or elsewhere.

Although the doctors' groups have considered a years-long moratorium, they decided to let the FDA set the time span, depending on whether the drug or device breaks new ground.

According to physicians several patients demand inappropriate drugs after being exposed to a drug company's advertisement. Drug makers have said the ads educate the public and only advise patients to ask their doctors.

The house of delegates of the AMA which set the group's policy at its annual meeting has recommended that the FDA pre-approve such advertisements, ensuring that they are based on objective information from clinical trials that would reveal the balance between a product's benefits and risks, as well as define warnings and potential adverse reactions properly.

The AMA's president-elect, Dr. Ronald Davis said, 'Physicians will have the opportunity to become better educated on the pros and cons of prescription drug uses before prescribing them, and will be better able to determine when they are best suited for their patients' medical needs.'

A drug industry group has said that it shared the AMA's goal of educating the public which was proved by last year's agreement among manufacturers to voluntarily inform the health-care community before launching consumer ads.

Dr. Paul Antony of the Pharmaceutical Research and Manufacturers of America said, 'The length of time this requires will vary from medicine to medicine, and companies will likely meet this goal in different ways.'

High-profile drugs like Vioxx was withdrawn by Merck in 2004 following the development of problematic side affects like an increase in heart attacks and strokes. Vioxx was popularized because of its huge advertising budget.

AMA' s decision came following argument by some plaintiffs in lawsuits that Merck continued to promote the painkiller despite knowledge that it carried risks.


'"/>




Related medicine news :

1. Anti-tobacco Advertising Can Reduces smoking Among Teens
2. New Rule Results In The Complete Makeover In The Field Of Drug Advertising
3. Subliminal Advertising works
4. Pfizer Commences Its Advertising for Celebrex with All the Warnings
5. Tobacco Advertising Through Movies Luring Kids
6. Advertising Blamed For Kids Poor Choices
7. CDC Uses Advertising Campaign to Get Kids Moving
8. Synova Acquires Rights to Today Sponge Contraceptive, Plans Advertising Campaign
9. Body mass index guide needs revision
10. Risk of heart disease prediction needs updating
11. Air pollution combined with greater medical needs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... ... 06, 2016 , ... Experimentation involving human stem cells (HSCs) ... to its potential for revolutionizing human disease treatment. There are multiple HSC platforms ... cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, but what ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... TopConsumerReviews.com recently ... Mobility Scooters . , Mobility Scooters give freedom to people who need help ... Still others may be facing a long period of rehabilitation after an illness or ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... CRANBURY, N.J. , Dec. 5, 2016 /PRNewswire/ ... pharmaceutical company, today presented data from two Phase ... poster sessions at the 58th annual meeting of ... San Diego, California . The two ... patients with acute myeloid leukemia (AML) and T-cell ...
(Date:12/5/2016)... Dec. 5, 2016   Lexicon Pharmaceuticals, Inc. ... from a Phase 2 clinical study of sotagliflozin, a ... collaboration with JDRF, the leading global organization funding type ... Phase 2 clinical trial, which randomized a total of ... once-daily 400 mg dose of sotagliflozin compared to a ...
(Date:12/5/2016)... 5, 2016  Sharn Anesthesia Inc. announced today that ... distribution partner for Salter Labs.  The company also received ... recognition of outstanding sales performance. Salter Labs ... anesthesia care, including the market gold standard ECO 2 ... distributor of the Parker Flex-Tip® Endotracheal Tube, which is ...
Breaking Medicine Technology: